LUND, Sweden, April 8, 2021 /PRNewswire/ -- BioInvent
International AB (publ) (Nasdaq Stockholm: BINV) today announced
that the Annual Report for 2020 is published and available at the
company's website, www.bioinvent.com.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a
clinical-stage company that discovers and develops novel and
first-in-class immuno-modulatory antibodies for cancer therapy,
with currently three drug candidates in four ongoing clinical
programs in Phase l/ll trials for the treatment of hematological
cancer and solid tumors, respectively. The Company's validated,
proprietary F.I.R.S.Tâ„¢ technology platform simultaneously
identifies both targets and the antibodies that bind to them,
generating many promising new drug candidates to fuel the Company's
own clinical development pipeline or for additional licensing and
partnering.
The Company generates revenues from research collaborations and
license agreements with multiple top-tier pharmaceutical companies,
as well as from producing antibodies for third parties in the
Company's fully integrated manufacturing unit. More information is
available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
This information is such information as BioInvent
International AB (publ) is obliged to make public pursuant to the
Swedish Securities Markets Act. The information was submitted for
publication, through the agency of the contact person set out
above, at 8:30 a.m. CEST on
April 8, 2021.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bioinvent-international-ab/r/bioinvent-international-s-annual-report-2020-published,c3321301
The following files are available for download:
https://mb.cision.com/Main/583/3321301/1398389.pdf
|
BioInvent Annual
Report 2020
|
https://mb.cision.com/Public/583/3321301/8c7dbd70905437fb.pdf
|
210408 Annual Report
2020 Eng
|